Wockhardt Drug Gets India's First U.S. QIDP Fast-Track Status
This article was originally published in PharmAsia News
Executive Summary
Wockhardt has become the first India drug maker to receive U.S. FDA Qualified Infectious Disease Product status, a fast-track review designation, for two versions of its anti-MRSA drug.